Brief: MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
04/06/2024 13:47
June 4 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY REVEALS NEW CLINICAL DATA SHOWING
THIO'S
STRONG EFFICACY IN NON-SMALL CELL LUNG CANCER
* MAIA BIOTECHNOLOGY INC - TO DATE, TREATMENT WITH THIO +
CEMIPLIMAB HAS BEEN GENERALLY WELL TOLERATED IN A HEAVILY
PRE-TREATED PATIENT POPULATION
* MAIA BIOTECHNOLOGY INC - ANTICIPATE FULL EFFICACY DATA
FROM
THIO-101 IN SECOND HALF OF THIS YEAR
Source text for Eikon: ID:nBw4KX21ha
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale